ECSP088172A - Metodos para tratar la epileptogenesis - Google Patents
Metodos para tratar la epileptogenesisInfo
- Publication number
- ECSP088172A ECSP088172A EC2008008172A ECSP088172A ECSP088172A EC SP088172 A ECSP088172 A EC SP088172A EC 2008008172 A EC2008008172 A EC 2008008172A EC SP088172 A ECSP088172 A EC SP088172A EC SP088172 A ECSP088172 A EC SP088172A
- Authority
- EC
- Ecuador
- Prior art keywords
- group
- phenyl
- alkyl
- methods
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta invención está dirigida a métodos para prevenir, tratar, invertir, inhibir o detener la epileptogénesis en un sujeto, que comprende administrar al sujeto en necesidad del mismo, una cantidad terapéuticamente efectiva de un compuesto seleccionado del grupo que consiste en la Fórmula (I) y la Fórmula (II), o una sal o éster farmacéuticamente aceptable del mismo:en donde el fenilo está sustituido en X con uno a cinco átomos de halógeno, seleccionados del grupo que consiste en flúor, cloro, bromo y yodo y, R1, R2, R3, R4, R5 y R6 se seleccionan de manera independiente del grupo que consiste en hidrógeno y alquilo de C1-C4; en donde el alquilo de C1-C4 está sustituido opcionalmente con fenilo (en donde el fenilo está sustituido opcionalmente con sustituyentes, seleccionados de manera independiente del grupo que consiste en halógeno, alquilo de C1-C4, alcoxi de C1?C4, amino, nitro y ciano).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69862505P | 2005-07-12 | 2005-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088172A true ECSP088172A (es) | 2008-03-26 |
Family
ID=37637731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008172A ECSP088172A (es) | 2005-07-12 | 2008-02-12 | Metodos para tratar la epileptogenesis |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070021501A1 (es) |
| EP (1) | EP1906946A2 (es) |
| JP (1) | JP2009501223A (es) |
| KR (1) | KR20080028485A (es) |
| CN (1) | CN101309680A (es) |
| AR (1) | AR054550A1 (es) |
| AU (1) | AU2006269462A1 (es) |
| BR (1) | BRPI0613010A2 (es) |
| CA (1) | CA2615127A1 (es) |
| EA (1) | EA200800295A1 (es) |
| EC (1) | ECSP088172A (es) |
| IL (1) | IL188728A0 (es) |
| NO (1) | NO20080739L (es) |
| TW (1) | TW200744575A (es) |
| WO (1) | WO2007008551A2 (es) |
| ZA (1) | ZA200801402B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102088990A (zh) * | 2008-05-16 | 2011-06-08 | 阿尔伯维塔公司 | 癫痫的治疗 |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| JP6062077B2 (ja) | 2013-03-12 | 2017-01-18 | バイオ−ファーム ソリューションズ カンパニー リミテッド | 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物{phenylcarbamatecompoundsforuseinpreventingortreatingpediatricepilesyandepilesy−relatedsyndromes} |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| KR102615486B1 (ko) * | 2015-08-24 | 2023-12-19 | 조게닉스 인터내셔널 리미티드 | 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법 |
| CN109071424B (zh) * | 2016-02-29 | 2022-01-14 | 生物药品解决方案有限公司 | 氨基磺酸酯衍生物化合物、其制备方法及用途 |
| US20190022166A1 (en) * | 2017-07-18 | 2019-01-24 | Creative Bio-Peptides Inc. | Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders |
| USRE50630E1 (en) | 2017-10-31 | 2025-10-14 | Creative BioPeptides, Inc. | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain |
| CN109920550A (zh) * | 2018-12-25 | 2019-06-21 | 天津大学 | 一种基于dMRI研究青少年肌阵挛性癫痫的方法 |
| US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
| CN115501344A (zh) * | 2022-09-29 | 2022-12-23 | 重庆医科大学 | 一种铁螯合剂的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| AU3304997A (en) * | 1996-05-31 | 1998-01-05 | Southern Illinois University | Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation |
| JP2002536409A (ja) * | 1999-02-09 | 2002-10-29 | ユニバーシティ オブ バージニア パテント ファウンデーション | フェルバメートから誘導される化合物 |
| DE60223506T2 (de) * | 2001-02-27 | 2008-09-18 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen |
| HUP0303243A3 (en) * | 2001-02-27 | 2012-07-30 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing and treating bipolar disorder |
-
2006
- 2006-07-06 US US11/481,626 patent/US20070021501A1/en not_active Abandoned
- 2006-07-07 WO PCT/US2006/026277 patent/WO2007008551A2/en not_active Ceased
- 2006-07-07 CA CA002615127A patent/CA2615127A1/en not_active Abandoned
- 2006-07-07 JP JP2008521432A patent/JP2009501223A/ja not_active Withdrawn
- 2006-07-07 CN CNA2006800333910A patent/CN101309680A/zh active Pending
- 2006-07-07 BR BRPI0613010-0A patent/BRPI0613010A2/pt not_active IP Right Cessation
- 2006-07-07 EP EP06786434A patent/EP1906946A2/en not_active Withdrawn
- 2006-07-07 KR KR1020087003269A patent/KR20080028485A/ko not_active Withdrawn
- 2006-07-07 AU AU2006269462A patent/AU2006269462A1/en not_active Abandoned
- 2006-07-07 EA EA200800295A patent/EA200800295A1/ru unknown
- 2006-07-11 AR ARP060102976A patent/AR054550A1/es not_active Application Discontinuation
- 2006-07-11 TW TW095125162A patent/TW200744575A/zh unknown
-
2008
- 2008-01-10 IL IL188728A patent/IL188728A0/en unknown
- 2008-02-11 ZA ZA200801402A patent/ZA200801402B/xx unknown
- 2008-02-11 NO NO20080739A patent/NO20080739L/no not_active Application Discontinuation
- 2008-02-12 EC EC2008008172A patent/ECSP088172A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009501223A (ja) | 2009-01-15 |
| TW200744575A (en) | 2007-12-16 |
| BRPI0613010A2 (pt) | 2010-12-14 |
| KR20080028485A (ko) | 2008-03-31 |
| CA2615127A1 (en) | 2007-01-18 |
| CN101309680A (zh) | 2008-11-19 |
| WO2007008551A3 (en) | 2008-06-19 |
| US20070021501A1 (en) | 2007-01-25 |
| EP1906946A2 (en) | 2008-04-09 |
| AR054550A1 (es) | 2007-06-27 |
| EA200800295A1 (ru) | 2008-12-30 |
| WO2007008551A2 (en) | 2007-01-18 |
| AU2006269462A1 (en) | 2007-01-18 |
| NO20080739L (no) | 2008-04-10 |
| ZA200801402B (en) | 2009-10-28 |
| IL188728A0 (en) | 2008-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088179A (es) | Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos | |
| NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
| CO6180427A2 (es) | Tratamiento de los trastornos generalizados del desarrollo | |
| NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
| ECSP077395A (es) | Compuesto de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos | |
| AR033426A1 (es) | Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento | |
| AR054550A1 (es) | Metodos para tratar la epileptogenesis | |
| PT1408953E (pt) | Compostos carbamato para utilizacao na prevencao ou tratamento do disturbio bipolar | |
| CO6180505A2 (es) | Metodos para el tratamiento de transtornos cocleares y vestibulares | |
| BR0207673A (pt) | Compostos de carbamato para o uso no tratamento de dor | |
| EA200701536A1 (ru) | Способы контроля интервала qt | |
| BR0207829A (pt) | Composto de carbamato para uso na prevenção ou tratamento de distúrbios psicóticos | |
| CO6160292A2 (es) | Metodos de tratamiento de transtornos de comportamiento perturbador 877 | |
| UY29158A1 (es) | Metodos de tratamiento de la epileptogénesis y la epilepsia | |
| CR9766A (es) | Metodos para el tratamiento de trastornos relacionados con sustancias | |
| AR035757A1 (es) | Uso de carbamatos para la fabricacion de medicamentos para prevenir o tratar un trastorno bipolar | |
| MY149385A (en) | Methods for treating substance-related disorders |